Platelet Function Testing in Cardiovascular Diseases
Platelets have an increasingly welldefined critical role in coronary artery thrombosis 3 and in other common car-diovascular diseases, including stroke, peripheral vascular disease, and diabetes mellitus. 1 Although the role of platelets in thrombosis is well characterized, platelets may also have a role in the pathogenesis of the underlying atherosclerotic process. 3 Platelet function tests have been studied in cardiovascular disease as a means to predict clinical outcomes and to monitor antiplatelet drugs. Table 1 summarizes these tests.
Use of Platelet Function Tests to Predict Clinical Outcomes
In acute coronary syndromes and after coronary stenting, flow cytometric analysis of platelet activation-dependent markers predicts major adverse cardiac events (MACE). 5 Increased platelet surface P-selectin is also a risk factor for silent cerebral infarction in patients with atrial fibrillation. 6 However, circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than is platelet surface P-selectin in the clinical settings of stable coronary artery disease, 7 human percutaneous coronary intervention, 8 and acute myocardial infarction. 8 Furthermore, circulating monocyte-platelet aggregates are an early marker of acute myocardial in-farction. 9 Measurement of plasma CD40L in the first 12 hours after the onset of ischemic symptoms in patients with unstable angina identifies a subgroup of patients that gains a much greater clinical benefit from abciximab treatment. 10 High plasma concentrations of sCD40L may be associated with increased cardiovascular risk in apparently healthy women. 11 In patients with stable angina, the Platelet Function Analyzer-100 (PFA-100; Dade Behring) closure time may predict the presence or absence of coronary artery stenoses at angiography, thereby potentially avoiding further diagnostic investigations. 12 PFA-100 closure time may also be predictive of the severity of myocardial damage in acute myocardial infarction. 13 In summary, although a number of studies have demonstrated that platelet function tests can predict MACE in cardiovascular diseases, none of these assays have been sufficiently studied in large clinical trials to become part of standard clinical care.
Use of Platelet Function Tests to Monitor Antiplatelet Drugs
Aspirin reduces the odds of a serious arterial thrombotic event in high-risk patients by Ϸ25%. 14 However, 10% to 20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up. 14 The failure of aspirin to prevent an arterial thrombotic event has been termed aspirin resistance. The failure of clopidogrel to prevent an arterial thrombotic event has been termed clopidogrel resistance. Similarly, the term GP IIb/IIIa antagonist resistance could be used. Because arterial thrombosis is multifactorial, an adverse arterial thrombotic outcome in a patient may often reflect treatment failure rather than resistance to an antiplatelet drug. Furthermore, patient noncompliance with aspirin, clopidogrel, or both is a frequent and hard-to-detect confounding problem. There is welldocumented variability between patients (and "normal" volunteers) with regard to laboratory test responses to aspirin, [15] [16] [17] [18] [19] [20] thienopyridines, 21 and GP IIb/IIIa antagonists. 22 This variability in laboratory test response has also been termed "resistance" to antiplatelet agents. The key question is: Do laboratory tests of resistance to aspirin, clopidogrel, or GP IIb/IIIa antagonists predict clinical resistance to these drugs (ie, MACE)? Clinically meaningful definitions of aspirin, clopidogrel, and GP IIb/IIIa antagonist resistance can be based only on data linking drug-dependent laboratory tests to clinical outcomes in patients. Until such links are clearly established, MACE that occur despite an antiplatelet agent should not be termed drug resistance.
Aspirin
Aspirin irreversibly acetylates serine 530 of cyclooxygenase-1 (COX-1), resulting in the inhibition of thromboxane A 2 release from platelets and prostacyclin from endothelial cells. Because platelets lack the synthetic machinery to generate significant amounts of new COX, aspirin-induced COX-1 inhibition lasts for the lifetime of the platelet. In contrast, endothelial cells retain their capacity to generate new COX and recover normal function shortly after exposure to aspirin. Possible mechanisms of aspirin resistance are listed in Table 2 .
There is evidence that MACE in the settings of acute coronary syndromes, stroke/ transient ischemic attacks, and peripheral arterial disease can be predicted by the following in vitro tests of aspirin resistance: arachidonic acid-and ADPinduced platelet aggregation (turbidometric), ADP-and collagen-induced platelet aggregation (impedance), Veri-fyNow (Accumetrics), PFA-100, or urinary 11-dehydrothromboxane B 2 (Figure TRAP indicates thrombin receptor-activating peptide; VASP, vasodilator-stimulated phosphoprotein; CV, coefficient of variation; GPV, glycoprotein V; and RPFA, rapid platelet function analyzer (Accumetrics). For further information on these tests, see reference 1.
*No published studies address the clinical effectiveness of altering therapy based on a laboratory finding of resistance to aspirin, clopidogrel, or GP IIb/IIIa antagonists.
2A). [15] [16] [17] [18] [19] [20] However, in all of these studies, the number of MACE was low.
Thienopyridines
The thienopyridines clopidogrel (Plavix, Bristol-Myers Squibb/ Sanofi Aventis) and ticlopidine (Ticlid, Bristol-Myers Squibb/Sanofi Aventis) inhibit ADP from binding to its platelet surface P2Y 12 receptor. Possible mechanisms of clopidogrel resistance are listed in Table 2 . Matetzky et al found evidence that an in vitro test of clopidogrel resistance (ADP-induced platelet aggregation) predicts MACE, but the number of MACE was again low (Figure 2B ). 21 The P2Y 12 H2 haplotype is reported to be associated with peripheral artery disease. 23
GP IIb/IIIa Antagonists
The GP IIb/IIIa antagonists abciximab (ReoPro, Eli Lilly/Centocor), eptifi-batide (Integrilin, Millennium Pharmaceuticals), and tirofiban (Aggrastat, Merck) inhibit fibrinogen from binding to platelet surface GP IIb/IIIa (integrin ␣ IIb ␤ 3 ), the final common pathway of platelet aggregation. Although the term resistance has not been used in the literature with regard to GP IIb/IIIa antagonists, there is substantial patient-to-patient variability in the degree of inhibition of platelet function by GP IIb/IIIa antagonists. 22 Furthermore, there is evidence that an in vitro test of abciximab resistance (Veri-fyNow) predicts MACE ( Figure 2C ). 22
Treatment for Resistance to Antiplatelet Agents
Although some clinicians change treatment on the basis of platelet function testing, 24 the correct treatment, if any, of aspirin resistance is unknown. Noncompliance should be considered. Increasing the dose of aspirin is unlikely to be helpful. 14 Interference NSAID coadministration (competes with aspirin for serine 530 of COX-1)
Atorvastatin (interferes with cytochrome P 450 -mediated metabolism of clopidogrel)
Platelet function
Incomplete suppression of thromboxane A 2 generation (aspirin) Accelerated platelet turnover, with introduction into bloodstream of newly formed, drug-unaffected platelets Stress-induced COX-2 in platelets (aspirin)
Increased platelet sensitivity to ADP and collagen

Single-nucleotide polymorphisms
Receptors: P2Y 12 H2 haplotype (clopidogrel), GP IIb/IIIa, collagen receptor, thromboxane receptor, etc Enzymes: COX-1, COX-2, thromboxane A 2 synthase, etc (aspirin)
Platelet interactions with other blood cells
Endothelial cells and monocytes provide PGH 2 to platelets (bypassing COX-1) and synthesize their own thromboxane A 2 (aspirin)
Other factors
Smoking, hypercholesterolemia, etc
Rather than resistance, is it:
Aspirin or clopidogrel response variability?
Platelet response variability?
Treatment failure (because arterial thrombosis is multifactorial)? 
